SpyGlass Pharma, Inc. (SGP) fair value analysis
Nasdaq · Updated 2026-10-19
SGP price how computed
Valuation status
No fair-value estimate yetSGP has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for SGP yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $24.00
- Sector
- Healthcare
- 12-month range
- $18.32–$26.86
- Market cap
- $803M
- From 52-week high
- -10.6%
- Shares outstanding
- 33.4M
- Rank in Healthcare by quality score
- #264 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
SpyGlass Pharma, Inc. is a healthcare company that develops and commercializes pharmaceutical products focused on treatments for various disease areas. The company operates in the United States and serves patients through its product portfolio and distribution channels.
SGP currently ranks #264 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $803M
- Debt / equity
- 0.01
- Shares outstanding
- 33.4M
Derived indicators how computed
- Quality grade
- F
- 52-week position
- The upper-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 33 · neutral
Earnings how computed
- Next earnings report
- 2026-11-05
- Last 3 quarters vs consensus
- 1 beat, 2 missed
- Quarter by quarter
- 2026-06 ▼ miss (-22.9%)
2026-03 ▼ miss (-91.7%)
2025-12 ▲ beat (+21.5%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 6 buy · 0 hold · 0 sell (6 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $44
- Target vs last price
- +83.3%
What our data shows for SGP
- Shares are trading in the middle of their 12-month price range of $18.32–$26.86.
- The 14-day relative strength index sits at a neutral 33.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- SGP's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the SGP conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is SGP stock undervalued?
TickrTrends has no fair-value estimate for SGP yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is SGP's TickrTrends verdict?
SGP is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does SGP compare to other Healthcare stocks?
SGP ranks #264 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is SGP overbought or oversold?
SGP's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does SGP report earnings next?
SGP's next earnings report is scheduled for 2026-11-05, per the published earnings calendar.
Does SGP usually beat earnings estimates?
Over its last 3 reported quarters SGP beat the consensus estimate 1 times and missed 2 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about SGP?
Of 6 analysts covering SGP, 6 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $44 (+83.3% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.